Answers are grounded in this paper and cite their sources.
Efficacy measures in SLE trials show significant improvements in outcomes, indicating strong utility for clinical assessments.
The SLE-DAS RI is a robust efficacy end point in SLE trials, associated with sustained disease control and meaningful improvements in patient-reported outcomes. SLE-DAS also enables accurate identification of MSDA, supporting its broader utility in trial design.
No takes yet. Share an insight, caveat, or question.
Jesus et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: